NEW YORK, June 13 – The life sciences division of Shimadzu has agreed to purchase Qiagen Genomics’ SNP analysis platform and license the technology, the companies said Wednesday.

The non-exclusive agreement calls for Shimadzu to purchase Qiagen Genomics’ genotyping chemistry and instrumentation for five years. Shimadzu of Japan will use the equipment to provide genotyping services to Japanese customers.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.